MCS compared with GMAB: revenue, margins and what each company keeps, and the suppliers and customers both name

MCSMarcus Corp

Mkt capRevenueRevenue

GMABGenmab A/S

Mkt capRevenueRevenue

Compare

MCSMarcus Corp

GMABGenmab A/S

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

GMAB: latest quarter not drawable.Method ›

Price

rebased to 0%

MCS, solidGMAB, dashed

MCSMarcus Corp

26.56▼−5.39%· post 26.56

Mkt cap$825.5MRevenue$238MQ3 FY26Revenue$758MFY25

GMABGenmab A/S

57.03▲+0.96%· post 57.15

ClosedOct 30 '26

Mkt cap$36.7BRevenue—Revenue—

Compare

ClosedOct 30 '26

MCSMarcus Corp

GMABGenmab A/S

26.56▼−5.39%post 26.56

Price

57.03▲+0.96%post 57.15

$825.5M

Mkt cap

$36.7B

Q3 FY26$238M

Revenue

—

FY25$758M

Revenue

—

MCS26.56▼−5.39%vsGMAB57.03▲+0.96%ClosedOct 30 '26

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only MCS 0

None

Shared 0

No disclosed counterparties: MCS.

Only GMAB 1

COAGHemab Therapeuticscustomer

Role chip = supplier or customerSource: SEC EDGAR